Lecirelin Acetate

Cancer like syndrome is a series of symptoms caused by the secretion of various bioactive substances by cancer like cells, such as 5-hydroxytryptamine (5-HT), bradykinin, etc. These substances can cause physiological changes such as abnormal gastrointestinal motility and vasodilation. Sufferers often experience severe diarrhea, intermittent skin flushing, and abdominal pain, which seriously affect their quality of life. As a long-acting somatostatin analogue, it can precisely act on cancer like cells and related tissues. It reduces the substances that cause symptoms at the source by inhibiting the secretion of serotonin by cancer like cells.

At the same time, it can also regulate the movement function of the gastrointestinal tract, restoring its normal rhythm and effectively relieving diarrhea symptoms. In terms of flushing symptoms, by inhibiting the release of vasodilator related substances, reducing abnormal vasodilation of blood vessels, the frequency and severity of flushing attacks can be lowered. For abdominal pain, it exerts a relieving effect by reducing intestinal spasms and inflammatory reactions.

In clinical treatment, it has significant advantages.

In the past, sufferers often needed frequent injections of short acting somatostatin analogs, such as octreotide, which not only caused inconvenience to suffererts but also increased the risk of infection and other complications. And its long-term characteristics greatly reduce injection frequency and improve sufferer compliance. Research has shown that after standardized treatment with (D-TLE6)-LEUPROLIDE, the frequency of diarrhea in sufferers can be reduced by 50% -70%, which means that sufferers' lives can be greatly improved and they will no longer be troubled by frequent diarrhea. At the same time, the frequency of flushing can be reduced by 60% -80%, and sufferers no longer feel embarrassed and uncomfortable due to sudden flushing, resulting in a significant improvement in their quality of life.

Gastroesophageal reflux disease is a common digestive system disease, mainly caused by excessive secretion of gastric acid and relaxation of the lower esophageal sphincter, resulting in the reflux of gastric contents into the esophagus, causing symptoms such as heartburn, acid reflux, and chest pain. Long term repeated reflux can also damage the esophageal mucosa, leading to complications such as esophagitis and esophageal stenosis. Plays an important role in the treatment of gastroesophageal reflux disease. It can inhibit the secretion of gastric acid, reduce the acidity in the stomach, and reduce the stimulation of gastric acid on the esophageal mucosa. At the same time, it can enhance the tension of the lower esophageal sphincter, prevent gastric contents reflux, and reduce the occurrence of reflux events from two aspects.

For sufferers with poor efficacy of proton pump inhibitors (PPIs) or requiring long-term maintenance therapy, a new treatment option is provided. PPI is currently a commonly used medication for the treatment of gastroesophageal reflux disease, but some sufferers may not have ideal therapeutic effects on PPI, or long-term use of PPI may result in some adverse reactions. The emergence of lecirelin acetate has brought hope to these sufferers. Clinical studies have shown that after treatment, sufferers' reflux symptom scores can be reduced by 40% -60%, indicating significant relief of symptoms such as heartburn and acid reflux. Moreover, it can improve esophageal mucosal damage, promote the repair of esophageal mucosa, reduce the occurrence of complications, and improve the quality of life of sufferers.

Pancreatitis is a disease of the pancreas caused by the self digestion of trypsin, which can be divided into acute pancreatitis and chronic pancreatitis. Acute pancreatitis has a sudden onset and a dangerous condition, which can cause symptoms such as abdominal pain, nausea, vomiting, and fever. In severe cases, it can lead to multiple organ dysfunction syndrome. Chronic pancreatitis is mainly characterized by recurrent abdominal pain and pancreatic dysfunction. It plays an important role in the treatment of pancreatitis.

It can inhibit the secretion of pancreatic enzymes, reduce the digestive effect of pancreatic enzymes on pancreatic tissues, and thus alleviate the inflammatory response of the pancreas. Meanwhile, it can also inhibit the exocrine function of the pancreas, reduce its burden, and facilitate its repair and recovery.

In the adjuvant treatment of acute pancreatitis, it can alleviate sufferers' abdominal pain symptoms, reduce the occurrence of complications, and shorten hospitalization time.

Research shows that after treatment, sufferers' hospitalization time can be shortened by about 30%, which not only reduces their economic burden but also improves the efficiency of medical resource utilization. For sufferers with chronic pancreatitis, pain can be effectively controlled and their quality of life can be improved. In addition, it can also reduce the risk of pseudocyst formation. Pseudo cyst is one of the common complications of pancreatitis, which can cause serious consequences such as compression symptoms and infection. By alleviating pancreatitis and promoting pancreatic repair, the chance of pseudocyst formation is reduced.

The immune system plays an important role in the occurrence, development, and regression of tumors. Dendritic cells are important antigen-presenting cells in the immune system, capable of absorbing, processing, and presenting tumor antigens, activating T cells, and triggering anti-tumor immune responses. T cell subpopulations include helper T cells (Th), cytotoxic T cells (Tc), and regulatory T cells (Treg), which play different roles in anti-tumor immunity. It has an immunomodulatory effect, which can regulate the function of dendritic cells, enhance their antigen presentation ability, and enable T cells to better recognize and attack tumor cells. At the same time, it can also regulate the balance of T cell subsets, increase the number and activity of cytotoxic T cells, reduce the inhibitory effect of regulatory T cells, and enhance anti-tumor immune response.

Immune checkpoint inhibitors, such as PD-1 antibodies, have been a major breakthrough in the field of cancer treatment in recent years. They can alleviate the suppression of the immune system by tumor cells and activate the body's anti-tumor immune response. However, not all sufferers respond to immune checkpoint inhibitor therapy. Can be used as an adjuvant therapy drug for immune checkpoint inhibitors to improve sufferer response rates. Research has shown that when used in combination with immune checkpoint inhibitors, the response rate of sufferers can be increased by about 20%, which means that more sufferers can benefit from immunotherapy, prolong survival, and improve quality of life.

Sleep disorders are one of the common symptoms in cancer sufferers, and factors such as tumor related fatigue, neuroendocrine disorders, and psychological stress can all lead to insomnia and decreased sleep quality. Long term sleep disorders can affect sufferers' physical recovery, immune function, and mental health. (D-TLE6)-LEUPROLIDE has a central sedative effect and can regulate the gamma aminobutyric acid and dopamine systems. Gamma aminobutyric acid is an important inhibitory neurotransmitter that can suppress neuronal excitability and promote sleep. Dopamine is related to physiological functions such as wakefulness and attention. By regulating the balance between these two systems, the sufferer's nervous system is in a relaxed state, thereby improving insomnia or sleep quality.

(D-TLE6)-LEUPROLIDE has significant therapeutic effects on sleep disorders caused by cancer-related fatigue or neuroendocrine disorders. Research has shown that after treatment, sufferers' sleep time can be shortened by 30% -50%, which means that sufferers can enter sleep faster and reduce the trouble caused by difficulty falling asleep. At the same time, the proportion of deep sleep can be increased by 20% -30%. Deep sleep is an important stage for the body's recovery and repair during sleep. Increasing the proportion of deep sleep can help improve the sufferer's physical recovery ability and immune function, and improve the overall health status of the sufferer.

During the development of the disease, cancer sufferers often experience malnutrition, mainly due to factors such as tumor depletion, digestive and absorption dysfunction, and treatment side effects. Malnutrition can affect the treatment effectiveness, quality of life, and survival of sufferers. Plays an important role in maintaining the nutritional status of cancer sufferers. It can promote the repair of gastrointestinal mucosa, which is an important site for digestion and absorption. Repairing damaged mucosa can improve digestion and absorption function, allowing sufferers to better absorb and utilize nutrients. At the same time, it can also increase the psufferer's appetite, encouraging them to actively eat and consume more nutrients.

For sufferers with advanced cancer, supportive treatment with lecirelin acetate is particularly important. Research has shown that after treatment, the protein synthesis rate of sufferers can be increased by about 15% -20%. Protein is an important component of body cells, and increasing the protein synthesis rate helps maintain normal physiological functions and repair damaged tissues. Moreover, it can reduce weight loss, keep suffererts in good physical condition, improve their tolerance to treatment, and enhance their quality of life.